The Covid-19 pandemic, devastating as it is, is producing some triumphs of collaborative research and innovation, as everyone from the World Health Organization to national laboratories, pharmaceutical companies, and Facebook groups of engineers race to fight the virus. But lurking behind this remarkable work is a threat: Some individuals or companies may exploit patents to profiteer off the crisis and could slow these innovative efforts to a crawl.

In this time of crisis, lawmakers must be wary of patents and be flexible and proactive in using the many legal tools available to check their harmful use. (See link for article)



Great reminder of an all important topic Lyme/MSIDS patients are all too aware of: conflicts of interests slowing or even stopping true scientific progress.

Recently, regarding COVID-19, I posted that the Chinese are trying to patent the anti-viral, Remdesivir: is currently a clinical trial for Remdesivir in which they are finding:

rapid recoveries in fever and respiratory symptoms, with nearly all patients discharged in less than a week.

A similar effect was found in rhesus monkeys:

Regarding Lyme/MSIDS, microbiologist Tom Greer recently wrote an excellent letter outlining this problem of conflicts of interests and patents:

A while back, I too wrote an article highlighting the problems with the faulty research that continues to be done – ignoring an entire LARGE subset of people who have remaining symptoms:  The authorities continue to fixate on the acute stage of the disease as well as insist upon having positive blood serology when research has proven Lyme tests relying upon antibodies to be worthless. They also insist that patients have the EM rash to enter studies, when research also shows many never get a rash.

For more on Lyme testing:


The 1994 serodiagnostic testing guidelines predated a full understanding of key B. burgdorferi antigens and have a number of shortcomings. These serologic tests cannot distinguish active infection, past infection, or reinfection.